Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Infectious Complications And Preventative Strategies Following Chimeric Antigen Receptor T-Cells (Car-T Cells) Therapy For B-Cell Malignancies, Alfadil Haroon, Ibrahim N. Muhsen, Muhammad Bilal Abid, Abdulwahab Albabtain, Ali Alahmari, Syed Osman Ahmed, Riad El Fakih, Mahmoud Aljurf
Infectious Complications And Preventative Strategies Following Chimeric Antigen Receptor T-Cells (Car-T Cells) Therapy For B-Cell Malignancies, Alfadil Haroon, Ibrahim N. Muhsen, Muhammad Bilal Abid, Abdulwahab Albabtain, Ali Alahmari, Syed Osman Ahmed, Riad El Fakih, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Several chimeric antigen receptor T-cell constructs (CAR-T cells) are currently approved for the treatment of B-cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia. Additionally, multiple other products are being investigated and developed for other hematological malignancies and solid cancers. Patients receiving CAR-T cells are at increased risk of infectious complications that lead to increased morbidity and inferior mortality in these patients. In this review, we discuss the literature on the incidence and types of infection in patients in the early and late-phase after CAR-T cells infusion. Additionally, we summarize the current literature on prophylaxis against viral, bacterial, and fungal …
Adoptive Cellular Therapy In Acute Myeloid Leukemia: Current Scope And Challenges, Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S Majhail
Adoptive Cellular Therapy In Acute Myeloid Leukemia: Current Scope And Challenges, Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S Majhail
Hematology/Oncology and Stem Cell Therapy
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These novel therapies targeting disease specific antigens such as CD19 in lymphoma and B cell maturation antigen in multiple myeloma have been shown to be efficacious and reasonably well tolerated, especially when compared to conventional chemotherapies. Unfortunately, their potential has not been realized in acute myeloid leukemia (AML). This can be attributed to the fact that most targetable antigens on AML cells are also expressed on healthy myeloid hematopoietic stem cells (HSC); targeting them results in severe myeloablative effects and pancytopenia. Over the years, several …